To see if a drug administered via injection (dupilumab) is safe and effective at reducing eosinophilic inflammation in the stomach of participants with eosinophilic gastritis (EG)/ eosinophilic gastroenteritis (EGE).
Thank you for your interest, but this study is not currently enrolling.
United States (Nationwide)
Evan Dellon
Medicine-Gastroenterology
Clinical or Medical
Interventional
Stomach, Digestion and Gut Health
21-0025
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
